CoChat

Targeting IgE in Severe Atopic Dermatitis with a Combination of Immunoadsorption and Omalizumab

Open access
Zink, A, Gensbaur, A, Zirbs, M, Seifert, F, Suarez, I, Mourantchanian, V, Weidinger, S, Mempel, M, Ring, J, Ollert, M · 2016 · Acta Dermato Venereologica

The DOI matches its Crossref record; 33 of the 33 references it cites were found in a registry or an index.

Abstract

Patients with atopic dermatitis (AD) tend to have greatly elevated levels of serum immunoglobulin E (IgE). However, the role of IgE in the pathogenesis of AD is debated. This investigator-initiated open-label pilot study evaluates an anti-IgE-treatment approach by combining extracorporeal immunoadsorption and anti-IgE antibody omalizumab in 10 patients with severe, therapy-refractory AD. IgE levels decreased after immunoadsorption and decreased continuously in all patients during anti-IgE therapy. The reverse trend was observed during 6 months follow-up without treatment. In parallel with these observations, an improvement in AD was observed during the treatment period, with aggravation during follow-up. Further research is needed, based on the principle of reducing IgE levels in order to improve clinical symptoms, using a combination anti-IgE treatment approach, adjusted according to IgE levels.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.2340/00015555-2165

Cites

33 of 33 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Research works printed but not linked: 3

  1. [2]2. Bieber T. Atopic dermatitis. Ann Dermatol 2010; 22: 125-137.
  2. [5]5. Kim DH, Park KY, Kim BJ, Kim MN, Mun SK. Antiimmunoglobulin E in the treatment of refractory atopic dermatitis. Clin Exp Dermatol 2013; 38: 496-500.
  3. [21]21. Jung T, Stingl G. Atopic dermatitis: therapeutic concepts evolving from newpathophysiologic insights. J Allergy Clin Immunol 2008; 122: 1074-1081.

Cited by

See all 69

Metadata

Authors
Zink, A., Gensbaur, A., Zirbs, M., Seifert, F., Suarez, I., Mourantchanian, V, Weidinger, S., Mempel, M., Ring, J., & Ollert, M.
Affiliations
  • Technical University of Munich (DE)
  • TUM Klinikum (DE)
  • Christian-Albrechts-Universität zu Kiel (DE)
  • Helmholtz Munich (DE)
  • University of Southern Denmark (DK)
Venue
Acta Dermato Venereologica
Published
2016
Volume
96
Issue
1
Pages
72-76
ISSN
0001-5555 (ISSN-L)
OpenAlex
W1817989193
Cited by
67
References
32
Citations by year
2025: 5 · 2024: 1 · 2023: 6 · 2022: 3 · 2021: 10 · 2020: 2 · 2019: 9 · 2018: 10 · 2017: 11 · 2016: 9
FWCI
11.57
Type
journal article
Language
en
Open access
Licence
cc-by-nc
Locations
  • Acta Dermato Venereologica (publishedVersion, cc-by-nc)
  • PubMed (publishedVersion)
  • University of Southern Denmark Research Portal (University of Southern Denmark) (publishedVersion, other-oa)
  • PuSH - Publication Server of Helmholtz Zentrum München (submittedVersion, cc-by-nc)
  • mediaTUM – the media and publications repository of the Technical University Munich (Technical University Munich) (submittedVersion, other-oa)
  • mediaTUM (Technical University of Munich) (submittedVersion)
  • Site cant be reached (submittedVersion, cc-by-nc)
Funders
  • Deutsche Forschungsgemeinschaft
  • Technische Universität München
Topics
  • Health Sciences › Medicine › Dermatology › Dermatology and Skin Diseases
  • Health Sciences › Medicine › Pulmonary and Respiratory Medicine › Asthma and respiratory diseases
  • Health Sciences › Medicine › Dermatology › Contact Dermatitis and Allergies
Keywords
atopic dermatitis, immunoglobulin E, omalizumab, extracorporeal immunoadsorption, anti-IgE therapy, IgE levels, treatment response
MeSH terms
Omalizumab, Adult, Aged, Blood Component Removal, Combined Modality Therapy, Dermatitis, Atopic, Female, Humans, Immunoglobulin E, Immunosorbent Techniques, Male, Middle Aged, Pilot Projects, Remission Induction, Severity of Illness Index, Time Factors, Biomarkers, Treatment Outcome, Disease Progression, Anti-Allergic Agents

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.